MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate's ...

Noise-canceling headphones are great for blocking out distractions, but they can also block out sounds you actually need to hear, like a courier at the front door with your all-important package. Well ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented at the ...